The agency, whose plan to expand its oversight of laboratory testing was the subject of a House hearing, also March 21, has said it could not endorse the 5-FU toxicity tests because it’s never ...

The utility of these markers to predict toxicity in specific patients is less clear. Ongoing studies are needed to clarify the role of 5-FU biomarkers in predicting efficacy and toxicity before ...

In the United States, about 275,000 patients with cancer receive 5-FU each year ... are estimated to die each year from the drug’s toxicity. The side effects are most severe for patients ...

During the first cycle of capecitabine development, three concomitant drugs were found to affect 5-FU clearance. [5] Paracetamol and morphine increased 5-FU clearance by 26% and 41%, respectively ...